Skip to content

Source filing unavailable

Q1 2017 · —
Revenue$140.00Kno prior Q1 2016 on fileno prior Q4 2016 on file
Net Income-$5.88MN/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$21.60N/M vs Q1 2016N/M vs Q4 2016
Operating Income-$7,599,000—
Operating Cash Flow-$6,979,000—
Margins · derived
Operating margin-5427.9%
Net margin-4197.1%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2017Q1 2016
Revenue$140.00K—
Net Income-$5.88M-$5.91M
EPS Diluted-$21.60-$21.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR